<DOC>
	<DOCNO>NCT02465528</DOCNO>
	<brief_summary>This Proof-of-Concept ( POC ) study assess preliminary antitumor activity safety tolerablity use ceritinib ( LDK378 ) treatment life threaten tumor characterize ALK genetic alteration ( and/or overexpression disease ) .</brief_summary>
	<brief_title>Ceritinib Rare Indications Study ALK+ Tumors</brief_title>
	<detailed_description />
	<mesh_term>Ceritinib</mesh_term>
	<criteria>Patient histologically cytologically confirm diagnosis ALK positive ( ALK+ ) NonSmall Cell Lung Cancer ( NSCLC ) . Patient must provide archival fresh tumor tissue first dose study drug ALK test Novartis designated central laboratory . Patient WHO Performance Status ( PS ) â‰¤ 2 Patient must receive least one line prior systemic treatment recurrent , locally advanced and/or metastatic disease , may discontinue : Disease progression define RECIST 1.1 solid tumor ; RANO GBM Cheson assessment criterion lymphoma Intolerance described discontinuation due AE grade despite appropriate supportive treatment Patient least one measurable lesion define appropriate guideline . A lesion previously irradiate site may count target lesion clear sign progression since irradiation . Patient ALK+lung cancer Patient symptomatic CNS metastasis neurologically unstable require increase dos steroid within 2 week prior study entry manage CNS symptom . Patient acute chronic GI disease may significantly alter absorption ceritinib . Patient history pancreatitis history increase amylase lipase due pancreatic disease . Patient history interstitial lung disease interstitial pneumonitis , include clinically significant radiation pneumonitis . Patient clinically significant , uncontrolled heart disease and/or recent cardiac event ( within 6 month ) . Patient evidence active viral hepatitis , include Hepatitis A , B C ( test viral hepatitis mandatory ) . Patient known diagnosis human immunodeficiency virus ( HIV ) infection ( HIV test mandatory ) .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>ALK</keyword>
	<keyword>NSCLC</keyword>
	<keyword>hematological malignancy</keyword>
</DOC>